Alphabet’s bets on health tech are paying off as portfolio corporations scamper public
Here are the five companies, what they do, and when GV invested: Spero Therapeutics, a biopharmaceutical company creating treatments for bacterial infections, started trading on the Nasdaq last fall and has a current market cap of $204.8 million. GV led its Series C in March 2017 and its stake is now worth $15.79 million, according…

Commentaires récents